Cost-effectiveness of nivolumab in the treatment of head and neck cancer.

A Hirschmann,J E Lupatsch,M Schwenkglenks, C M Panje,K Matter-Walstra,V Espeli,K J Dedes,M Siano

Oral Oncology（2018）

引用 13|浏览13

暂无评分

摘要

•Cost-effectiveness of nivolumab for HNSCC including follow-up data was assessed.•From the Swiss health care perspective the ICER was 102,957CHF per QALY.•Follow-up data is essential for modelling for more precise estimations of the ICER.

查看译文

关键词

Cost-effectiveness,Immunotherapy,Nivolumab,Head and neck cancer,Checkmate 141

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要